The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. AN2 Therapeutics Inc shares valued at $70,840 were purchased by Readnour Robin Shane on Nov 27 ’24. At $1.42 per share, Readnour Robin Shane acquired 50,000 shares. The insider’s holdings grew to 622,573 shares worth approximately $0.85 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Readnour Robin Shane purchased 25,000 shares, netting a total of over 34,845 in proceeds. Following the buying of shares at $1.39 each, the insider now holds 597,573 shares.
Before that, Zakrzewski Joseph S had added 2,000 shares to its account. In a trade valued at $2,800, the Director bought AN2 Therapeutics Inc shares for $1.40 each. Upon closing the transaction, the insider’s holdings increased to 2,000 shares, worth approximately $0.17 million.
As published in a research note from Leerink Partners on August 09, 2024, AN2 Therapeutics Inc [ANTX] has been rated down from an Outperform to a Market perform and the price target has been revised to $1 from $5. Analysts at Evercore ISI downgraded the stock from ‘”an In-line”‘ to ‘”an Underperform”‘ outlook in a report released in early August. As of July 03, 2024, Leerink Partners has increased its “Market perform” rating to a “an Outperform” for ANTX. Earlier on April 02, 2024, JMP Securities upgraded its rating. Their new recommendation was “a Mkt outperform” for ANTX stock which previously was a “a Mkt perform”.
Analyzing ANTX Stock Performance
During the last five days, there has been a surge of approximately 5.38%. Over the course of the year, AN2 Therapeutics Inc shares have dropped approximately -93.31%. Shares of the company reached a 52-week high of $22.2200 on 01/10/24 and a 52-week low of $0.8700 on 08/09/24. A 50-day SMA is recorded $1.0927, while a 200-day SMA reached $2.0249. Nevertheless, trading volume fell to 0.58 million shares from 0.48 million shares the previous day.
Support And Resistance Levels for AN2 Therapeutics Inc (ANTX)
According to the 24-hour chart, there is a support level at 1.3233, which, if violated, would cause prices to drop to 1.2767. In the upper region, resistance lies at 1.4333. The next price resistance is at 1.4967. RSI (Relative Strength Index) is 71.56 on the 14-day chart, showing overbought technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.2162, which suggests the price will decrease in the coming days. Percent R is at 18.56%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.
